By Jacqueline Howard; CNN
Most places in the United States with heavy monkeypox caseloads have shifted their vaccination strategies to the Biden administration's low-dose, intradermal approach -- and they are reporting varying results so far.
Some say the shift has stretched their vaccine supply, helping them meet a growing demand for the Jynneos monkeypox vaccine. Others report a hurdle -- while the new method should allow for five small doses of vaccine to be extracted from a single vial, they have only been able to extract about four.
The situation "does vary geographically," Claire Hannan, executive director of the Association of Immunization Managers, wrote in an email to CNN.
About three-quarters of jurisdictions in the United States have shifted to using the intradermal method of administering monkeypox vaccine, Bob Fenton, the White House's national monkeypox response coordinator, said in a briefing Friday.
"As of today, 75% of jurisdictions are already applying intradermal administration of vaccine, and another 20% are working to move in that direction," Fenton said.
Hannan shared similar results in her email to CNN based on a recent survey of immunization managers. When asked "Has your jurisdiction implemented the intradermal vaccination strategy?," 74% of survey respondents reported yes, 3% no, and 24% reported "partially."
So far, the US Department of Health and Human Services' Administration for Strategic Preparedness and Response has made a total of 1.1 million vials of Bavarian Nordic's Jynneos monkeypox vaccine available for free to jurisdictions to support monkeypox response efforts.
In early August, the US Food and Drug Administration issued an emergency use authorization allowing for health care providers to have the option of administering the Jynneos monkeypox vaccine intradermally, meaning between the layers of the skin, rather than subcutaneously, or in the fatty layer below the skin, which had been the typical way the vaccine was injected.
Continue reading on CNN.com.